- Home
- LMB vs GHRS Comparison
LMB vs GHRS Comparison
Compare LMB & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LMB | GHRS |
|---|---|---|
| Founded | 1901 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 914.9M | 892.0M |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LMB | GHRS |
|---|---|---|
| Price | $83.30 | $15.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $133.50 | $30.11 |
| AVG Volume (30 Days) | 150.3K | ★ 241.1K |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.03 | N/A |
| EPS | ★ 3.03 | N/A |
| Revenue | ★ $603,582,000.00 | N/A |
| Revenue This Year | $28.00 | N/A |
| Revenue Next Year | $13.48 | N/A |
| P/E Ratio | $26.11 | ★ N/A |
| Revenue Growth | ★ 16.56 | N/A |
| 52 Week Low | $63.02 | $7.20 |
| 52 Week High | $154.05 | $20.50 |
Technical Indicators
Market Signals| Indicator | LMB | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 63.05 | 67.27 |
| Support Level | $76.30 | $12.40 |
| Resistance Level | $80.23 | $13.33 |
| Average True Range (ATR) | 3.34 | 0.84 |
| MACD | 0.54 | 0.18 |
| Stochastic Oscillator | 90.25 | 49.14 |
Price Performance
Historical ComparisonAbout LMB Limbach Holdings Inc.
Limbach Holdings Inc is a commercial specialty contractor in the fields of heating, ventilation, air conditioning, plumbing, electrical, and building controls for the design and construction of new and renovated buildings, maintenance services, energy retrofits, and equipment upgrades. It operates in two segments namely General Contractor Relationships (GCR) and Owner Direct Relationships (ODR). The company generates maximum revenue from the ODR segment.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.